Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma
Phase 2
- Conditions
- thyroid carcinoma1005254710014713
- Registration Number
- NL-OMON31009
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
· Patients with non-medullary thyroid carcinoma
· The patients must have undergone total thyroidectomy
· Presence of metastases or inoperable recurrent disease, as proven by elevated serum thyroglobulin levels (Tg) in combination with radiological evidence for tumor.
· No or insufficient RaI uptake in tumor as proven by RaI scintigraphy, performed after prior RaI therapy.
Exclusion Criteria
· Pregnancy
· Other active malignancies
· Active kidney, liver or pancreatic disease or dysfunction
· Unstable angina pectoris or recent (<3 months) myocardial infarction.
· Coagulopathy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method